ArticleJournal of virology2015
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.
Open access · bronzeAbstract readComparative Study
In one paragraph
Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 45 citations in OpenAlex.
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.Science translational medicine · 2019Trial
- Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.The Journal of infectious diseases · 2018Trial
- Trial
- A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.Vaccines · 2025Article
- Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.Frontiers in immunology · 2022Article
- Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.iScience · 2021Article
- Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.Journal of virology · 2020Article
- Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs.NPJ vaccines · 2020Article
- Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1.Human vaccines & immunotherapeutics · 2020Article
- Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.Cell reports · 2020Article
- HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens.Scientific reports · 2020Article
- Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.Cell reports · 2020Article
- ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.PLoS pathogens · 2019Article
- Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.Cell host & microbe · 2019Article
- V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.Vaccines · 2019Review
- Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes.Journal of virology · 2019Article
- Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.Journal of virology · 2019Article
- HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 16 institutions in 5 countries.
Xiaoying ShenDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA sxshen@duke.edu gdt@duke.edu.
Ryan DuffyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Robert HowingtonDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Alethea CopeMucosal Infection & Immunity Group, Section of Infectious Diseases, Imperial College London, London, United Kingdom.
Shanmugalakshmi SadagopalDepartment of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Haesun ParkVaccine & Gene Therapy Institute (VGTI), Oregon Health & Science University, Portland, Oregon, USA.
Ranajit PalAdvanced Bioscience Laboratories Inc., Rockville, Maryland, USA.
Suefen KwaDepartment of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Song DingLaboratory of AIDS Immunopathogenesis, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Otto O YangDepartment of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA AIDS Healthcare Foundation, Los Angeles, California, USA.
Genevieve G FoudaDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Roger Le GrandCEA, Division of Immuno-Virology-IMDIT Center, DSV, iMETI, Fontenay-aux-Roses, Inserm-U1184, Université Paris-Sud, Orsay, France.
Diane BoltonVaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
Mariano EstebanDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Sanjay PhogatSanofi Pasteur, Swiftwater, PA, USA.
Mario RoedererVaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
Rama R AmaraDepartment of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Louis J PickerVaccine & Gene Therapy Institute (VGTI), Oregon Health & Science University, Portland, Oregon, USA.
Robert A SederVaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Susan BarnettNovartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA.
Sallie R PermarDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Robin ShattockMucosal Infection & Immunity Group, Section of Infectious Diseases, Imperial College London, London, United Kingdom.
Anthony L DeVicoInstitute for Human Virology, Baltimore, Maryland, USA.
Barbara K FelberHuman Retrovirus Pathogenesis Section, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
George N PavlakisHuman Retrovirus Section, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Giuseppe PantaleoLaboratory of AIDS Immunopathogenesis, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Bette T KorberTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Álamos, New Mexico, USA.
David C MontefioriDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA sxshen@duke.edu gdt@duke.edu.
Duke Medical Center · USEmory University · USDuke University Hospital · USImperial College London · GBOregon Health & Science University · USUniversity Hospital of Lausanne · CHAdvanced Bioscience Laboratories (United States) · USAIDS Healthcare Foundation · USCEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FRCenter for Cancer Research · USCentro Nacional de Biotecnología · ESFred Hutch Cancer Center · USLos Alamos National Laboratory · USNational Cancer Institute · USNovartis (United States) · USSanofi (United States) · US
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MViral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI ALAM, S. MUNIR · 2006 to 2011
$290.5MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MPrevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0MImmunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6MDevelopment Of Flow Cytometric Technologies For Immune AssaysZIAAI005020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ROEDERER, MARIO · 2009 to 2019
$9.6MTransmission-blocking potential of novel HIV Env-specific mucosal antibodiesR01AI106380 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2013 to 2017
$3.4MAddressing Intra-/Inter-Clade Diversity in HIV Vaccine Design by Immune FocusingR21AI087382 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, OTTO O · 2010 to 2011
$448kNIAID NIH HHS 5U19AI067854NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI106380NIAID NIH HHS R01AI106380NIAID NIH HHS R21 AI087382NIAID NIH HHS R21 AI87382NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIH HHS P51 OD011132
Abstract
To evaluate antibody specificities induced by simian immunodeficiency virus (SIV) versus human immunodeficiency virus type 1 (HIV-1) envelope antigens in nonhuman primate (NHP), we profiled binding antibody responses to linear epitopes in NHP studies with HIV-1 or SIV immunogens. We found that, overall, HIV-1 Env IgG responses were dominated by V3, with the notable exception of the responses to the vaccine strain A244 Env that were dominated by V2, whereas the anti-SIVmac239 Env responses were dominated by V2 regardless of the vaccine regimen.
Indexed as
AnimalsAntibodies, ViralAntibody SpecificityEpitopesHIV-1Immunoglobulin GMicroarray AnalysisPrimatesSimian Immunodeficiency VirusSpecies SpecificityViral Envelope ProteinsAntibodies, ViralEpitopesImmunoglobulin GViral Envelope Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.